Opendata, web and dolomites

SULIPRO

A scientifically proven, safe, naturally derived drug for the effective treatment of liver damage - an innovative solution for a significant unmet medical need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SULIPRO project word cloud

Explore the words cloud of the SULIPRO project. It provides you a very rough idea of what is the project "SULIPRO" about.

trial    company    alcoholic    financial    once    cirrhosis    eur    ing    raised    online    fatty    web    private    transplant    botanical    successful    drug    fat    oral    amount    scientifically    population    demonstrating    models    safe    counter    treatment    nafld    26    maintains    humans    first    made    combination    builds    distributor    undergone    seriously    consumers    proven    diseases    price    preclude    food    patients    compounds    affordable    functions    nash    progress    permanent    parallel    natural    market    prescribed    showing    medical    specialised    drugs    shops    non    fda    otc    expects    months    supplements    commercialised    animal    positive    approved    sulipro    steatohepatitis    efficacy    liver    inflammation    death    impair    million    causing    therapeutic    unless    disease    clinical    stages    physician    soy    prevalence    33    amazon    24    funds    pharmacies    scarring    foods    shield    trials    small   

Project "SULIPRO" data sheet

The following table provides information about the project.

Coordinator
NATURAL SHIELD ISRAEL 2016 LIMITED 

Organization address
address: AD GORDON 13
city: HERZLIYA
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://natshield.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NATURAL SHIELD ISRAEL 2016 LIMITED IL (HERZLIYA) coordinator 50˙000.00

Map

 Project objective

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver causing inflammation and eventually lead to permanent scarring (cirrhosis), which can seriously impair the liver’s ability to functions. NAFLD can progress to non-alcoholic steatohepatitis (NASH), and then to liver failure resulting in death unless there is a liver transplant. The prevalence of NAFLD in Europe is estimated to be between 26 and 33% of the general population. Currently, there is no available therapeutic treatment for patients with NAFLD and NASH. Natural Shield have developed a specialised oral therapeutic, called SULIPRO, which is a combination of soy derived compounds, that has been proposed as a novel scientifically proven safe treatment for patients in the early stages of NAFLD and NASH. Current drugs produced for liver diseases have a large amount of side effects and high financial costs that may preclude their long-term use in patients with NAFLD or the early stages of NASH. SULIPRO has already undergone positive clinical trials in animal models and successful Phase I clinical trials in humans showing demonstrating no side effects and high efficacy. The company now requires funding for a small Phase II trial. Once commercialised SULIPRO will be made available to consumers at an affordable price, as an over the counter (OTC) drug, available in shops/pharmacies and on the web, using an online distributor, such as Amazon. Natural Shield maintains its own research program involved in developing in parallel OTC food supplements, physician-prescribed medical foods, and FDA-approved botanical drugs. The company expects to reach the market with its first products within 24 months and thus far has raised over 5 million EUR in private funds.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SULIPRO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SULIPRO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More